T imolol maleate, a nonselective beta-adrenergic blocker, is used as an ophthalmic solution for the treatment of glaucoma. It possesses the therapeutic advantage oflowering intraocular pressure without changing pupillary size or causing diminution of vision, side effects which are prominent with miotic medications such as pilocarpine.' Over half the reports of adverse reactions to timolol ophthalmic solution reflect systemic beta blockade due to absorption from the conj~nctiva.~Thus, therapeutic doses of timolol ophthalmic solution may cause a significant decrease in airflow in patients with bronchospastic pulmonary
Within 30 minutes of the administration of his first dose of timolol ophthalmic solution, a 6 7 -y e d d men with stable chronic obstructive pulmonary disease experienced severe dyspnea leading to respiratory arrest. He recovered after endotracheal intubation and mechanical ventilation. Patients with bronchospastic pulmonary disease who are candidates for therapy with timdol ophthalmic solution should receive their first dose under medical supervision and should have continued close medical follow-up for as long as they receive timold.
T imolol maleate, a nonselective beta-adrenergic blocker, is used as an ophthalmic solution for the treatment of glaucoma. It possesses the therapeutic advantage oflowering intraocular pressure without changing pupillary size or causing diminution of vision, side effects which are prominent with miotic medications such as pilocarpine.' Over half the reports of adverse reactions to timolol ophthalmic solution reflect systemic beta blockade due to absorption from the conj~nctiva.~Thus, therapeutic doses of timolol ophthalmic solution may cause a significant decrease in airflow in patients with bronchospastic pulmonary
The present case is important to note because the patient suffered a potentially fatal respiratory arrest within 30 minutes of his first dose of timolol ophthalmic solution.
A 67-yearold man had been receiving outpatient treatment for chronic obstructive pulmonary disease, noncritical calcific aortic stenosis, essential hypertension, and glaucoma His medicines included hvdrochlorothiazide. theoohvlline sustained-action tablets, and ietaproterenol sulfate, dotl; orally and by inhalation. sion, demonstrated moderate obstructive disease with air trapping. The forced vital capacity was 3.2 L, and the forced expiratory ~l u m e in one second was 1.76 L (55 percent). There was no significant change in flow rate following the administration of bronchodilator drugs. He had been clinically stable, except for worsening glaucoma.
On the day of admission, he had been seen in the ophthalmology clinic, and, because of progression of glaucoma despite pilocarpine therapy, timolol ophthalmic solution (0.5 percent) was prescribed. That evening, within approximately five minutes of his first dose of one drop in each eye, he noted the acute onset of shortness ofbreath. His symptoms were not relieved by three of four pu& from his metaproterenol inhaler. Over the next ten minutes, his dyspnea progressed rapidly, and his wife noted that he was markedly cyanotic. She summoned the paramedics; when they arrived, the patient was unresponsive and apneic. Assisted ventilation with an Ambu bag and supplemental oxygen were begun, and he was transferred to a nearby community hospital.
When he arrived in the emergency room, the pulse rate was 120 beatslmin and the blood pressure was 250/l20 mm Hg. There was no effective spontaneous respiration. The arterial blood gas levels were pH, 6.93; Pco,, 141 mm Hg; and Po,, 71 mm Hg. Following insertion of an endotracheal tube under morphine sedation, mechanical ventilation was begun. He received intravenously-administered arninophylline and steroids and aerosolized isoetharine hydrochloride. Forty minutes after intubation, hewas responsive and able to follow commands. His breath sounds were much improved, although bilateral wheezes were present. The arterial blood gas levels were pH, 7.07; Pco,, 83 mm Hg; and Po,, 197 mm Hg (fractional concentration ofoxygen in inspired gas [FIoJ, 0.50) . Two hours after intubation, the arterial blood gas levels (FIo,, 0.40) were: pH, 7.41; Pco*, 36 mm Hg; and P%, 191 mm Hg. Although intermittent wheezing persisted, the patient was successfully extubated 15 hours later.
We did not rechallenge our patient with timolol in view of the severity of his bronchospasm; however, the temporal relationship between his first dose of timolol and the subsequent respiratory arrest strongly implicated timolol as the inciting agent. Xmolol is known to be absorbed from the conjunctiva into the systemic circulationP bypassing the liver where it is normally metabolized. The relative potency of timolol is approximately six times that of propranolol%o that absorption of even the small doses of timolol used in ophthalmic solutions may cause systemic beta blockade. Patients with obstructive airway disease may be critically dependent upon beta-adrenergic stimulation for the maintenance of airway patency and thus be susceptible to severe and potentially fatal bronchospasm following the administration of tirnolol solution. In such patients, timolol ophthalmic solution should be considered only as a last resort when other methods of therapy have failed to control glaucoma. When timolol therapy is contemplated in a patient with obstructive airway disease, it may be helpful to perform spirometric evaluation before and after topical administration of timolol to determine if clinically inapparent bronchospasm is provoked.' We believe that patients with clinical evidence of increased airway reactivity should receive the initial dose of timolol ophthalmic solution under medical observation and that personnel and facilities should be available to perform resuscitation, ifneeded. Even ifthere is no apparent adverse reaction to the first dose, continued close medical follow-up is mandatory throughout the course of timolol therapy. ,452-year-old male retired laundry worker with a history of Graves' disease and atrial fibrillation with congestive heart failure secondary to rapid rate, was evaluated for chest pain. The chest pain was first noted in 1978 and described as left-sided precordial tightness associated with dyspneaand occasionally radiating to the right chest. The pain occurred once weekly, and was not associated with exertion. In July, 1980 he sought medical attention for palpitations, chest pain and dyspnea. He was noted to be hyperthyroid with atrial fibrillation and mild congestive heart failure. There was no enzvme -or electmcardiographic evidence of infarction or ischemia. He was treated with digitalis, furosemide and propranolol in addition to 6.03 mci of U'I. He was euthyroid for the subsequent six months, but suffered relapse in M& 1981 which was treated with propyl-*From the Department of Medicine, Veterans Administration Medical Center, and Brown University, Providence, Rhode Island. +Assistant Professor in Medicine. $Clinical Assistant Professor in Medicine.
thiouracil.
The previous infrequent episodes of chest discomfort increased in frequency to once daily during 1981. The pain continued to be leftsided precordial tightness and occurred predominantly at rest. It typically lasted less than ten minutes and persisted for three to five minutes after nitroglycerin. It was usually associated with diaphoresis and dyspnea and rarely with dizziness. While the episodes were somewhat more common in the evening, there was no clear relationship to eating. The tightness was unrelieved by ingestion of food. Superimposed on the episodic tightness was constant diffuse chest tightness which persisted for several hours or entire days and did not respond to administration of nitroglycerin. On seven occasions, the prolonged chest tightness resulted in admissions to the coronary &re unit. ~ssessment during episodes of d f i s e tightness or left-sided re cordial exacerbations demonstrated dia~horesis. Bushing and agitation. There were elevations in blood pressure without tachycardia, S,, or ECG changes. Therapeutic trials of nitrates and beta blockers as an outDatient had no effect on the frequency or severity of the chest discomfort.
The patient had a 35 pack-year history of smoking and rarely drank alcohol. He has a positive family history for coronary artery disease and two brothers had non-insulindependent diabetes mellitus. Endocrine tests confirmed thyrotoldcosis prior to YMI treatment including T,, 23.1 )~g/dl (4.5-ll.5); T, uptake, 51 percent (25-35). Vanilmandellic acid in 24 hours urine collection was 7.5 mg and 9.6 mg (1-12 mg124 hours). Urinary metanephrine level in 24 hours was 0.4 mg (0-1 mg). Unstimulated serum renin was 2.6 mg/ml/hour 11.43.8).
His &ac evaluation included an inconclusive exercise tolerance test in April, 1981 with failure to achieve target heart rate. (The peak heart rate was 145 at 9.5 minutes of exercise in the standard Bruce During an admission in September, 1981, an episode of the patient's typical chest dimmfort occurred late in the afternoon accompanied by symptoms of weakness, profuse diaphoresis, and near syncope. It was relieved after therapy with sublingual nitroglycerin and oxygen. A blood sugar level drawn at the time of the episode was 46 mg/dl. A five-hour oral glucose tolerance test with 100 g of glucose performed the following day (Table l) 
